JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Начало・Списък с акции・AbCellera Biologics Inc

AbCellera Biologics Inc

Затворен

СекторЗдравеопазване

4.13 -0.48

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.11

Максимум

4.37

Ключови измерители
By Trading Economics
Приходи	48M -8.9M
Продажби	36M 45M
Марж на печалбата	-19.942
Служители	562
EBITDA	22M -18M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+100.72% upside

Дивиденти
By Dow Jones
Следващи печалби	11.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	278M 1.2B
Предишно отваряне	4.61
Предишно затваряне	4.13

Настроения в новините

By Acuity

50%

157 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.99 / 2.635 Подкрепа & съпротива

AbCellera Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.04.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27.04.2026 г., 23:08 ч. UTC

Печалби

Значими двигатели на пазара

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27.04.2026 г., 23:30 ч. UTC

Пазарно говорене

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27.04.2026 г., 23:08 ч. UTC

Пазарно говорене

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27.04.2026 г., 22:42 ч. UTC

Пазарно говорене

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27.04.2026 г., 22:10 ч. UTC

Печалби

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27.04.2026 г., 21:56 ч. UTC

Печалби

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27.04.2026 г., 21:44 ч. UTC

Печалби

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27.04.2026 г., 21:43 ч. UTC

Печалби

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.04.2026 г., 20:39 ч. UTC

Печалби

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Сравнение с други в отрасъла

Ценова промяна

AbCellera Biologics Inc Прогноза

Ценова цел

By TipRanks

100.72% нагоре

12-месечна прогноза

Среден 8.33 USD 100.72%

Висок 11 USD

Нисък 7 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за AbCellera Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на AbCellera Biologics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.99 / 2.635Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Настроение

By Acuity

157 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.